學位

國防醫學院生命科學研究所博士

經歷

1.國防醫學院生命科學研究所助理教授

2.兼聘國防醫學院病理暨寄生蟲研究所助理教授

專長學科

生化及分子生物學、細胞分子生物學、腫瘤生物學

近年學術論文著作

1. Wu YS+, Ho JY+, Yu CP, Cho CJ, Wu CL, Huang CS, Gao HW, Yu DS. Ellagic Acid Resensitizes Gemcitabine-Resistant Bladder Cancer Cells by Inhibiting Epithelial-Mesenchymal Transition and Gemcitabine Transporters. Cancers (Basel). 2021 Apr 22;13(9):2032.

2. Lin TH, Gao HW, Liao GS, Yu JC, Dai MS, Ho JY*, Yu CP. Amongst Women Stratified to Receive Endocrine Therapy on the Basis of Their Tumor Estrogen and Progesterone Receptor Levels, Those with Higher Tumor Progesterone Receptor Levels Had a Better Outcome Than Those with Lower Levels of Tumor Progesterone Receptor. Cancers (Basel). 2021 Feb 21;13(4):905.

3. Cho CJ, Yu CP, Wu CL, Ho JY, Yang CW, Yu DS. Decreased drug resistance of bladder cancer using phytochemicals treatment. Kaohsiung J Med Sci. 2021 Feb;37(2):128-135.

4. Huang CS+, Ho JY+, Chiang JH, Yu CP, Yu DS. Exosome-Derived LINC00960 and LINC02470 Promote the Epithelial-Mesenchymal Transition and Aggressiveness of Bladder Cancer Cells. Cells. 2020 Jun 7;9(6):1419.

5. Cho CJ, Yang CW, Wu CL, Ho JY, Yu CP, Wu ST, Yu DS. The modulation study of multiple drug resistance in bladder cancer by curcumin and resveratrol. Oncol Lett. 2019 Dec;18(6):6869-6876.

6. Chen CC, Chen CY, Ueng SH, Hsueh C, Yeh CT, Ho JY, Chou LF, Wang TH. Corylin increases the sensitivity of hepatocellular carcinoma cells to chemotherapy through long noncoding RNA RAD51-AS1-mediated inhibition of DNA repair. Cell Death Dis. 2018 May 1;9(5):543.

7. Wu CL, Ho JY, Hung SH, Yu DS. miR-429 expression in bladder cancer and its correlation with tumor behavior and clinical outcome. Kaohsiung J Med Sci. 2018 Jun;34(6):335-340.

8. Ho JY, Hsu RJ, Liu JM, Chen SC, Liao GS, Gao HW, Yu CP. MicroRNA-382-5p aggravates breast cancer progression by regulating the RERG/Ras/ERK signaling axis. Oncotarget. 2017 Apr 4;8(14):22443-22459.